Novo Nordisk receives Investment Bank Analyst Rating Update
Investing.com – Denmark stocks were higher after the close on Friday, as gains in the Consumer Goods, Healthcare and Personal & Household Goods sectors led shares higher. At the...
Investing.com – Denmark stocks were higher after the close on Monday, as gains in the Consumer Goods, Personal & Household Goods and Healthcare sectors led shares higher. At the...
Inflation worries continue to weigh on equity marketsEarnings season will likely increase volatilityETFs offer investors ability to diversifyEarnings season has started with...
Reddit-hyped stocks slumpAlphabet, Amazon beat on earningsTech leads reflation trade rallyKey EventsUS futures contracts on the Dow, S&P, NASDAQ, and European stocks advanced...
Eli Lilly & Company (NYSE:LLY) announced that the FDA issued a complete response letter (“CRL”) for its supplemental new drug application (sNDA) seeking label...
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.